Expert Commentary on the Product Profile of Lazertinib in NSCLCByJenan Dailey, PharmD, BCAPOctober 23rd 2024Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.